An LRF-funded researcher earns a large research awards; round two of research funding process begins and a child's leukemia inspires A Beautiful Choice in this issue of Microscope.
One of the objectives for the Leukemia Research Foundation (LRF) in supporting research projects submitted by New Investigators is for those individuals to advance their research and, as a result, receive continued support in larger amounts from other funders. Jiwang Zhang, M.D., Ph.D.,
Hui Feng, M.D., Ph.D., Assistant Professor, Boston University School of Medicine, was funded by the LRF in 2015 for a research project titled Dissecting the Regulatory Role Of Dlst In Myc-Driven Leukemogenesis. She recently earned a 792,000 grant from the American Cancer Society and results from
An upcoming party for pediatric leukemia and lymphoma patients; an LRF-funded researcher earns a large research award; and commentary on the number of FDA-approved medications for AML can all be found in this issue of the Microscope.
Funded by the LRF in 2016-2017, Christopher Oakes, Ph.D. is featured in a video produced by the Video Journal of Hematological Oncology discussing chronic lymphocytic leukemia (CLL). In the video he described how new sequencing techniques have opened up the world of CLL research in ways not
The importance of supporting blood cancer research; news about an LRF-funded researcher earning a large research award from the National Institutes of Health, and information on an upcoming patient program - the Annual Town Hall Meeting, can all be found in this issue of the Microscope.
Feng Yue, Ph.D. (left), Assistant Professor of Biochemistry and Molecular Biology at Penn State College of Medicine, has received a five-year, 1.91 million Maximizing Investigators’ Research Award from the National Institutes of Health (NIH). Doctor Yue will use the funds to continue his work on
Samuel G. Katz, M.D., Ph.D. (left), Assistant Professor of Pathology at the Yale School of Medicine in Connecticut, is refining the science of cell and gene therapy. Click here to see how Dr.Katz is using ribonucleic acid (RNA) to reprogram cells to kill cancer cells. Doctor Katz was funded by
Letters on Intent for blood cancer research funding are now being accepted. There is also more perspective on the newly-approved CAR-T cell therapy and registration is open for the 24th Annual ABC 7 Gibbons 5K Run and 3K Walk.
The U.S. Food and Drug Administration (FDA) has approved Yescarta, a Car-T cell therapy, for lymphoma patients. Developed by Kite Pharma and Gilead Sciences, a Leukemia Research Foundation sponsor, the therapy involves removing a patient's own immune T-cells, reengineering them to recognize and